Hereditary Angioedema Hae — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hereditary angioedema hae . 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
8
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Hereditary Angioedema Hae

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kalvista 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hereditary angioedema hae . Each bar = one year. Y-axis scaled to peak year (5 patents).

5
35
2
37
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ekterly
SEBETRALSTAT
 Kalvista 8 53 — 2035-11-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11198691 Ekterly method of use 75 2035-11-26
11084809 Ekterly method of use 75 2035-11-26
10611758 Ekterly method of use 75 2035-11-26
11739068 Ekterly method of use 75 2037-06-23
11234939 Ekterly method of use 75 2039-01-26
11001578 Ekterly composition of matter 17 2035-11-26
10364238 Ekterly composition of matter 17 2035-11-26
11230537 Ekterly composition of matter 17 2037-12-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11230537 Ekterly composition of matter 17 2037-12-25
11001578 Ekterly composition of matter 17 2035-11-26
10364238 Ekterly composition of matter 17 2035-11-26
11234939 Ekterly method of use 75 2039-01-26
11739068 Ekterly method of use 75 2037-06-23
10611758 Ekterly method of use 75 2035-11-26
11198691 Ekterly method of use 75 2035-11-26
11084809 Ekterly method of use 75 2035-11-26

Related